What is GLEAMER?
GLEAMER operates at the intersection of deeptech and clinical radiology, providing AI-driven solutions designed to augment the capabilities of medical professionals. By automating the detection of abnormalities in medical images, the company addresses critical bottlenecks in diagnostic throughput and accuracy. Its market position is defined by a commitment to integrating seamlessly into existing hospital infrastructure, thereby reducing the cognitive load on radiologists and improving patient outcomes. As a key player in the European HealthTech ecosystem, GLEAMER utilizes its proprietary technology to set new standards for diagnostic precision in both hospital and private practice settings.
How much funding has GLEAMER raised?
GLEAMER has raised a total of $38.2M across 2 funding rounds:
Series A
$8.7M
Series B
$29.5M
Series A (2020): $8.7M with participation from Majycc eSanté Invest, XAnge, Crista Galli Ventures, Macsf, and Elaia
Series B (2023): $29.5M led by Bpifrance, Heal Capital, Supernova Invest, and XAnge
Key Investors in GLEAMER
Bpifrance
A French public investment bank that supports companies at every stage of development through credit, guarantees, and equity, with a strong focus on innovation and international growth.
Heal Capital
A specialized European venture capital firm focused on HealthTech and AI, providing both capital and direct access to healthcare systems for early-stage startups.
Supernova Invest
A deeptech-focused investment firm that provides patient capital and expertise to high-growth companies in the industrial, digital, and healthcare sectors.
What's next for GLEAMER?
Looking ahead, GLEAMER is poised to leverage its recent strategic investment to accelerate international expansion and deepen its product portfolio. The company's roadmap likely includes the integration of more complex diagnostic modules and the expansion of its footprint across global healthcare markets. With the backing of seasoned institutional investors, GLEAMER is expected to focus on scaling its operational capacity to meet the rising demand for AI-assisted diagnostics. The firm's ability to maintain its technological edge while navigating the complex regulatory environments of the medical sector will be the primary driver of its long-term valuation and industry influence.
See full GLEAMER company page
